SEC Form 4 · accession 0001140361-15-014287
SALIX PHARMACEUTICALS LTD · SLXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John F Chappell
Director
Period of report
Apr 1, 2015
Accepted (ET)
Apr 3, 2015 · 11:32 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001009356
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 1, 2015 | D | 294,120 | $173.00 | D | 0 | D | |
| Common Stock | Apr 1, 2015 | D | 28,644 | $173.00 | D | 0 | I | By Spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Pursuant to the terms of the Agreement and Plan of Merger, dated as of February 20, 2015 (as amended, the "Merger Agreement"), by and among the Issuer, Valeant Pharmaceuticals International ("VPI"), a Delaware corporation and a wholly owned subsidiary of Valeant, Sun Merger Sub, Inc. ("Merger Sub"), a Delaware corporation and a wholly owned subsidiary of VPI, and Valeant Pharmaceuticals International, Inc. ("Valeant"), a British Columbia corporation, on April 1, 2015, each share of the Issuer's common stock and each share of the Issuer's restricted stock issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement), other than shares then owned by Valeant, VPI, Merger Sub or by any of their wholly owned subsidiaries, and shares held by the Issuer or by any of its wholly owned subsidiaries, were converted into the right to receive $173.00 per share in cash, subject to any applicable withholding taxes.